Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Commvault Systems Inc (CVLT) Price & Performance

Abeona Therapeutics IncTrade
Commvault Systems IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Commvault Systems Inc — how do they compare? Abeona Therapeutics Inc trades at $7.56 (market cap $424.33M), while Commvault Systems Inc trades at $139.62 (market cap $5.78B). The key difference: Commvault Systems Inc is far larger — about 13.6× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Commvault Systems Inc nearer its low. Which is the better fit depends on your goals.

ABEOCVLT
Market Cap
$424.33M$5.78B
Sector
HealthTechnology
52-Week High
$7.45$195.41
52-Week Low
$4.17$75.18
Enterprise Value
$279.23M$5.77B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.

Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.

Commvault Systems Inc

Commvault Systems (CVLT) trades at $135.27, up 1.43% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with an 81.09% gross margin and 32.77% ROE, though valuation multiples like a P/E of 89.38 are elevated. Recent news highlights growth in SaaS revenue and new security integrations, such as the Threat Scan partnership with Google, driving positive analyst sentiment.

The outlook remains positive with a consensus price target of $172.40, implying 27% upside, supported by subscription growth and cash flow improvements. Risks include high valuation sensitivity, competitive pressures in data security, and fiduciary duty investigations noted in recent legal alerts, which could impact investor confidence near-term.

Returns comparison

Trailing returns across standard periods

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Commvault Systems Inc

Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.

Read more on CVLT